共 102 条
[1]
Kashgary A(2016)The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series BMC Nephrol 17 104-1270
[2]
Sontrop JM(2014)Ofatumumab for rituximab-resistant nephrotic syndrome N Engl J Med 370 1268-1239
[3]
Li L(2009)Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence Transplantation 87 1232-783
[4]
Al-Jaishi AA(2017)Keeping the customers stratified: moving toward genetics-based treatment options in childhood NS Kidney Int 91 781-1649
[5]
Habibullah ZN(2018)Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options Pediatr Nephrol 33 1641-2912
[6]
Alsolaimani R(2005)Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients Am J Transplant 5 2907-963
[7]
Clark WF(2018)Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre French cohort Nephrol Dial Transplant 33 954-528
[8]
Basu B(2018)Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies Pediatr Nephrol 33 527-1464
[9]
Hickson LJ(2014)Development of antirituximab antibodies in children with nephrotic syndrome Pediatr Nephrol 29 1461-1249
[10]
Gera M(2018)Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome Br J Clin Pharmacol 84 1238-841